Literature DB >> 20154583

Can the further clinical development of bevirimat be justified?

Mark A Wainberg, Jan Albert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20154583     DOI： 10.1097/QAD.0b013e328331c83b

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  7 in total

1.  Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity.

Authors:  Alicia Regueiro-Ren; Zheng Liu; Yan Chen; Ny Sin; Sing-Yuen Sit; Jacob J Swidorski; Jie Chen; Brian L Venables; Juliang Zhu; Beata Nowicka-Sans; Tricia Protack; Zeyu Lin; Brian Terry; Himadri Samanta; Sharon Zhang; Zhufang Li; Brett R Beno; Xiaohua S Huang; Sandhya Rahematpura; Dawn D Parker; Roy Haskell; Susan Jenkins; Kenneth S Santone; Mark I Cockett; Mark Krystal; Nicholas A Meanwell; Umesh Hanumegowda; Ira B Dicker
Journal:  ACS Med Chem Lett       Date:  2016-04-22       Impact factor: 4.345

2.  Improved Bevirimat resistance prediction by combination of structural and sequence-based classifiers.

Authors:  J Nikolaj Dybowski; Mona Riemenschneider; Sascha Hauke; Martin Pyka; Jens Verheyen; Daniel Hoffmann; Dominik Heider
Journal:  BioData Min       Date:  2011-11-14       Impact factor: 2.522

3.  Morphogenesis of the Infectious HIV-1 Virion.

Authors:  Jun-Ichi Sakuragi
Journal:  Front Microbiol       Date:  2011-12-09       Impact factor: 5.640

4.  Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.

Authors:  Zeyu Lin; Joseph Cantone; Hao Lu; Beata Nowicka-Sans; Tricia Protack; Tian Yuan; Hong Yang; Zheng Liu; Dieter Drexler; Alicia Regueiro-Ren; Nicholas A Meanwell; Mark Cockett; Mark Krystal; Max Lataillade; Ira B Dicker
Journal:  PLoS Pathog       Date:  2016-11-28       Impact factor: 6.823

5.  A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.

Authors:  Teodora Pene Dumitrescu; Samit R Joshi; Jianfeng Xu; Joyce Zhan; Mark Johnson; Laurie Butcher; Eric Zimmerman; Lindsey Webster; Antonia M Davidson; Max Lataillade; Sherene Min
Journal:  Antimicrob Agents Chemother       Date:  2021-05-18       Impact factor: 5.191

6.  The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects.

Authors:  Mark Johnson; Roxanne C Jewell; Amanda Peppercorn; Elizabeth Gould; Jianfeng Xu; Yu Lou; Matthew Davies; Sandra Baldwin; Allan R Tenorio; Matthew Burke; Jerry Jeffrey; Brian A Johns
Journal:  Pharmacol Res Perspect       Date:  2018-06-05

7.  Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor.

Authors:  Samit R Joshi; Disala Fernando; Stephanie Igwe; Litza McKenzie; Anu S Krishnatry; Fiona Halliday; Joyce Zhan; Thomas J Greene; Jianfeng Xu; Geraldine Ferron-Brady; Max Lataillade; Sherene Min
Journal:  Pharmacol Res Perspect       Date:  2020-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.